The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer

被引：1
|
作者：
Tripathy, Sambit [1 ]
机构：
[1] AIIMS, Dept Urol, Bhubaneswar, Odisha, India
来源：
INDIAN JOURNAL OF UROLOGY | 2021年 / 37卷 / 03期
关键词：
D O I：
10.4103/iju.IJU_542_20
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：293 / 294
页数：2
相关论文
共 50 条
  • [41] Re: Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2019, 201 (01): : 31 - 31
  • [42] Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer (vol 380, pg 1235, 2019)
    Fizazi, Karim
    Shore, Neal
    Tammela, Teuvo L.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (09): : 860 - 860
  • [43] Nonmetastatic Castration-Resistant Prostate Cancer
    Hong, Jun Hyuk
    Kim, Isaac Y.
    KOREAN JOURNAL OF UROLOGY, 2014, 55 (03) : 153 - 160
  • [44] DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Yu, Evan Y.
    Pieczonka, Christopher Michael
    Armstrong, Andrew J.
    Suzuki, Hiroyoshi
    Bailen, James L.
    Murphy, Declan G.
    Lebret, Thierry
    Luz, Murilo
    Thiery-Vuillemin, Antoine
    Ortiz, Jorge A.
    Khan, Javeed
    Briganti, Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17029 - E17029
  • [45] Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
    Aragon-Ching, Jeanny B.
    ASIAN JOURNAL OF ANDROLOGY, 2020, 22 (01) : 76 - 78
  • [46] Safety, tolerability, and duration of continued darolutamide treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study (ROS)
    Fizazi, K.
    Luz, M.
    Ulys, A.
    Ortiz, J.
    Srinivasan, S.
    Kurland, E.
    Shore, N. D.
    EUROPEAN UROLOGY, 2023, 83
  • [47] TREATMENT DURATION AND LONG-TERM SAFETY AND TOLERABILITY WITH DAROLUTAMIDE IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): ARAMIS ROLLOVER STUDY
    Shore, Neal D.
    Luz, Murilo
    Ulys, Albertas
    Ortiz, Jorge
    Srinivasan, Shankar
    Kurland, Etah
    Fizazi, Karim
    JOURNAL OF UROLOGY, 2023, 209 : E129 - E130
  • [48] Enzalutamide in Castration-Resistant Prostate Cancer
    Bregni, Giacomo
    Rebuzzi, Sara E.
    Fornarini, Giuseppe
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (14): : 1380 - 1381
  • [49] Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
    Tombal, B.
    Sternberg, C. N.
    Hussain, M.
    Ganguli, A.
    Li, Y.
    Sandin, R.
    Bhadauria, H.
    Oh, M.
    Saad, F.
    ESMO OPEN, 2022, 7 (03)
  • [50] Enzalutamide in castration-resistant prostate cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2014, 15 (08): : E312 - E312
12345